Venture Capital
Houston-based Alaunos (NASDAQ:TCRT), which changed its name from Ziopharm Oncology on January 26, is a small (~$200 million market cap) clinical-stage company focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer technology and its TCR library targeting tumor-specific oncogenic gene mutations called neoantigens. The TCR-T Library Phase 1/2 trial (TCR001-201) is an open label, dose escalation study being conducted by the renowned University of Texas MD Anderson Cancer Center. The next patient is anticipated to be treated sometime this quarter.

In this article